DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Issue 01 · Volume 50 · January 2012 DOI: 10.1055/s-002-22742


28. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
Hamburg, 27.–28. 1. 2012

Kongresspräsidentin: Prof. Dr. rer. nat. Gisa Tiegs
Abstracts (HTML) List of Authors
FV4_01
Langhans, B; Braunschweiger, I; Arndt, S; Sauerbruch, T; Spengler, U: Ribavirin beeinflusst unterschiedlich die Funktionen von CD4+ TH1-, TH2- und regulatoischen T-Zell-Klonen bei chronischer Hepatitis C
FV4_02
Abdulkarim, M; Wiegard, C; Glaubke, C; Lohse, AW; Schramm, C; Weiler-Normann, C: Atypische Präsentation der Primär biliären Zirrhose bei Männern
FV4_03
Frings, MK; Stabenow, D; Odenthal, M; Heikenwälder, M; Kashkar, H; Krönke, M; Knolle, PA: Viral infection sensitizes hepatocytes towards TNF-induced apoptosis
P4_01
Abdullah, Z; Riethausen, K; Geiger, S; Muralev, E; Tribica, J; Knolle, P: Hepatic fibrosis attenuates virus-specific CD8 T cell immunity causing virus persistence
P4_02
Albrecht, U; Kulawik, A; Raue, A; Timmer, J; Klingmüller, U; Häussinger, D; Bode, JG: Dynamic model of IL–6 and IL–1beta dependent signalling in primary murine hepatocytes
P4_03
Allweiss, L; Lütgehetmann, M; Volz, T; Helbig, M; Lohse, AW; Petersen, J; Ma, H; Klumpp, K; Fletcher, S; Dandri, M: TREATMENT WITH PEGYLATED INTERFERON-ALPHA INDUCES SUSTAINED SUPPRESSION OF BOTH VIRUS REPLICATION AND ANTIGENEMIA IN HUMANIZED uPA/SCID MICE STABLY INFECTED WITH HBV
P4_04
Amanzada, A; Lindhorst, A; Moriconi, F; Blaschke, M; Suermann, T; Mihm, S; Ramadori, G: Persistent HCV-infection and liver damage change vitamin-D-metabolism
P4_05
Amanzada, A; Lindhorst, A; Moriconi, F; Blaschke, M; Wietzke-Braun, P; Suermann, T; Mihm, S; Ramadori, G: IL28B allelic variation but not polymorphism of CYP27B1 or genotype of HCV is associated with spontaneous elimination of HCV-infection
P4_06
Amanzada, A; Schneider, S; Moriconi, F; Blaschke, M; Suermann, T; Mihm, S; Ramadori, G: IL28B genetic variation and ratio of y-GT/ALT as predictors for virological response in chronic hepatitis C virus genotype 1 infected patients
P4_07
Ayata, K; Idzko, M; Hasselblatt, P: P2Y2 receptor function aggravates acute hepatitis by regulating neutrophil infiltration and hepatocyte survival
P4_08
Bauer, T; Kutscher, S; Allgayer, S; Kittner, J; Schuchmann, M; Galle, PR; Sprinzl, MF; Protzer, U; Protzer, U: Add-on of pegylated interferon alpha–2a (PEG-IFN) triggers antigen-independent TNF-alpha production by CD4+ T cells in patients with pretreated chronic hepatitis B
P4_09
Beisel, C; Heuer, M; Schulze zur Wiesch, J; Zoufaly, A; Jochum, J; van Lunzen, J: Hepatitis C Therapie in HCV/HIV koinfizierten Patienten – eine monozentrische Kohortenstudie
P4_10
Beisel, C; Tóth, I; Scheurich, C; Matzat, V; Kummer, S; Lüth, S; van Lunzen, J; Hartjen, P; Lohse, A; Schulze zur Wiesch, J: Charakterisierung von B – Zell – Aktivierungs- und Koinhibitionsmarkern in Patienten mit chronischen Virusinfektionen (HBV; HCV)
P4_11
Bengsch, B; Seigel, B; Blum, HE; Thimme, R: Hierarchy of inhibitory receptor expression by Hepatitis B Virus (HBV)-specific CD8+ T cells in chronic HBV infection
P4_12
Böttcher, JP; Stabenow, D; Debey-Pascher, S; Staratschek-Jox, A; Grell, J; Höchst, B; Limmer, A; Atreya, I; Neurath, MF; Hegenbarth, S; Schmitt, E; Busch, DH; van Endert, P; Kolanus, W; Kurts, C; Schultze, JL; Diehl, L; Knolle, PA: Antigen cross-presentation in the liver generates protective memory CD8+ T cells in the absence of inflammation
P4_13
Bröring, R; Lutterbeck, M; Kleinehr, K; Paul, A; Gerken, G; Schlaak, JF: Toll-like receptor-activated primary human hepatocytes produce inflammatory cytokines and different types of interferon, resulting in HCV suppression in vitro
P4_14
Burghardt, S; Erhardt, A; Tiegs, G: The role of non-professional liver-resident APCs for inhibition of immune-mediated hepatitis in the mouse liver
P4_15
Churin, Y; Roderfeld, M; Mollenkopf, HJ; Glebe, D; Roeb, E: Hepatitis B virus surface proteins induce interferon response in the liver of HBV-transgenic mouse
P4_16
Claaß, B; Erhardt, A; Tiegs, G: Re-programming of Kupffer Cells for immune regulation in response to ConA-induced liver injury
P4_17
Dorn, C; Jilg, W; Heilmann, J; Hellerbrand, C: Xanthohumol inhibits hepatitis B virus replication in vitro
P4_18
Ehlting, C; Ronkina, N; Gaestel, M; Häussinger, D; Bode, JG: Distinct functions of the MAPKAP kinases MK2 and MK3 in the regulation of the inflammatory response in macrophages
P4_19
Eisenhardt, M; Glässner, A; Krämer, B; Sibbing, B; Sauerbruch, T; Spengler, U; Nattermann, J: Gestörte Funktion von CD56high CXCR3(+) NK Zellen als möglicher neuer Mechanismus der HCV-assoziierten Leberfibrose
P4_20
Erhardt, A; Kessler, T; Tiegs, G: The role of the IL–17 axis in a mouse model of drug-induced liver injury
P4_21
Fabian, J; Urban, S; Dooley, S; Meindl-Beinker, NM: Impact of HBV infection on TGF-β signaling in primary human hepatocytes
P4_22
Fabian, J; Dzieran, J; Dooley, S; Meindl-Beinker, NM: HCV core protein interferes with Smad1 and Smad3 dependent TGF-β signaling in HCC cells
P4_23
Gane, E; Deray, G; Piratvisuth, T; Chan, HLY; Jia, J; Ren, H; Rasenack, J; Manns, M; Amarapurkar, D; Dong, Y; Trylesinski, A: Telbivudine treatment improves renal function of Chronic Hepatitis B (CHB) patients
P4_24
Glässner, A; Eisenhardt, M; Krämer, B; Wolter, F; Kokordelis, P; Sibbing, B; Sauerbruch, T; Spengler, U; Nattermann, J: HCV-vermittelte Blockierung der IL–2 Sekretion von CD4(+) T-Zellen hemmt die anti-fibrotische Aktivität von NK-Zellen
P4_25
Helbig, M; Lütgehetmann, M; Volz, T; Allweiss, L; Lohse, AW; Petersen, J; Taylor, J; Dandri, M: HDV LACKING HBV CAN INFECT HUMAN HEPATOCYTES IN THE LIVER OF CHIMERIC uPA/SCID MICE AND PERSIST FOR AT LEAST SIX WEEKS BEFORE BEING RESCUED BY SUPERINFECTION WITH HBV
P4_26
Höchst, B; Schildberg, FA; Huss, S; Metzger, C; Knoblich, A; Schneider, B; Pantelis, D; Kalff, J; Knolle, P; Diehl, L: Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance to systemic circulating carcinoembryonic antigen: A new mechanism of Tumour-immune-Suppression
P4_27
Hohenester, S; Oude Elferink, R; Beuers, U: Antimitochondriale Antikörper sind ungeeignet zur Diagnose der Primär Biliären Zirrhose in Mäusen
P4_28
Huber, B; Wenzel, JJ; Leisner, U; Jilg, W: HBsAg-specific humoral and cellular immune responses in children and adolescents 8–14 years after vaccination against hepatitis B
P4_29
Hüppe, D; Mauss, S; Lutz, T; Schuchmann, M; Moog, G; Schober, A; Heyne, R; John, C; Schiffelholz, W; Eisenbach, C; Teuber, G; Baumgarten, A; Schott, E; Alshuth, U; Buggisch, P: Confirmation of high SVR rates after shortening duration of treatment with Peginterferon alfa–2a (PEG) and Ribavirin (RBV) in Chronic Hepatitis C (CHC) Patients with RVR in Real Life
P4_30
Joschko, N; Stremmel, W; Krammer, PH; Müller, M: Hepatitis B Virus Infection triggers AP–1 dependent CD95Ligand expression in HepG2 cells
P4_31
Kant, J; Möller, B; Heyne, R; Herber, A; Mössner, J; Berg, T; Wiegand, J: Evaluation of a rapid on-site anti-HCV test as screening tool for hepatitis C infection
P4_32
Kiraithe, MM; Nitschke, K; Thimme, R; Neumann-Haefelin, C: HLA-B27 has a dominant role in restricting strong CD8+ T cell responses and driving viral escape in hepatitis B virus infection
P4_33
Koletzko, L; Hellerbrand, C: Establishment of an in vitro model in which HBV promotes hepatocellular steatosis and lipotoxicity
P4_34
Krämer, B; Körner, C; Eisenhardt, M; Glässner, A; Zwank, C; Sibbing, B; Wolter, F; Kokordelis, P; Sauerbruch, T; Spengler, U; Nattermann, J: Der NKp46-Rezeptor ist an der Regulation der anti-fibrotischen Aktivität von NK Zellen beteiligt
P4_35
Langhans, B; Louis, M; Hüneburg, R; Oldenburg, J; Schultze, JL; Sauerbruch, T; Spengler, U: Adaptive CD4+ regulatorische T-Zellen regulieren die Fibrogenese durch Produktion von IL–8 bei chronischer Hepatitis C
P4_36
Leung, NWY; Herrmann, E; Chan, HLY; Lau, GK; Lee, K; Dong, Y; Trylesinski, A; Naoumov, NV; Zeuzem, S: Direkter Vergleich der Hepatitis B Viruskinetik während 12 Wochen mit Telbivudine (LDT) vs. Tenofovir (TDF) vs. Kombination LDT und TDF bei Patienten mit chronischer Hepatitis B
P4_37
Lütgehetmann, M; M´Barek, M; Volz, T; Allweiss, L; Helbig, M; Alexandrov, A; Lohse, AW; Petersen, J; Urban, S; Dandri, M: THE ENTRY INHIBITOR MYRCLUDEX-B EFFICIENTLY BLOCKS VIRAL SPREADING IN VIVO IN HUMAN LIVER CHIMERIC uPA/ SCID MICE PREVIOUSLY INFECTED WITH HEPATITIS B VIRUS
P4_38
Mauss, S; Hüppe, D; Lutz, T; Schober, A; Moog, G; Hey, KH; Schiffelholz, W; Teuber, G; Baumgarten, A; Schmidt, W; Stoehr, A; Waizmann, M; Isernhagen, K; Alshuth, U; Buggisch, P: Comparison of therapy outcome of patients with drug addiction (DA) versus patients with former iv drug use (IVDU) treated with Peginterferon alfa–2a/Ribavirin in real life setting
P4_39
Meiners, J; Heim, D; Lohse, AW; Wege, H: Differenzierte Untersuchung direkt karzinogener Effekte von HCV-Proteinen in immortalisierten humanen Hepatozyten
P4_40
Peiseler, M; Sebode, M; Katt, J; Franke, B; Wortmann, F; Quaas, A; Baron, U; Lohse, AW; Sobottka, I; Wiegard, C; Weiler-Normann, C; Herkel, J; Schramm, C: Patienten mit Primär Sklerosierender Cholangitis weisen ein gestörtes Gleichgewicht zwischen Foxp3+ regulatorischen T-Zellen und proinflammatorischen Th17 Zellen auf
P4_41
Pischke, S; Horn-Wichmann, R; Ernst, D; Meyer, BG; Raupach, R; Ahrenstorf, G; Schmidt, RE; Manns, MP; Witte, T; Wedemeyer, H: Chronic hepatitis E in patients with CVID in Germany?
P4_42
Real, CI; Bröring, R; John, M; Jahn-Hofmann, K; Ickenstein, L; Kleinehr, K; Gerken, G; Schlaak, JF: In vivo treatment with nanolipid-formulated siRNAs targeting ISG15 leads to enhanced responsiveness to interferon in primary hepatocytes
P4_43
Real, CI; Bröring, R; John, M; Jahn-Hofmann, K; Ickenstein, L; Kleinehr, K; Gerken, G; Schlaak, JF: Hepatic toll-like receptors can be activated by application of siRNAs in vivo via MyD88-dependent pathways which can be controlled by chemical ribose modifications of the siRNA backbone
P4_44
Resheq, Y; Quaas, A; von Renteln, D; von Renteln, D; Schramm, C; Lohse, AW; Lüth, S: IgG4-positive plasma cells can be elevated in malignant hepato-biliary and pancreatic diseases and do not allow discrimination between neoplastic and autoimmune disease
P4_45
Röder, C; Jordan, S; Hoepner, L; Pudelski, N; Supplieth, M; Lohse, AW; Schulze zur Wiesch, J; Lüth, S: Chronische Hepatitis C Infektion: Herausforderung Alter
P4_46
Roos, K; Haid, S; Herbst, A; Stremmel, W; Pietschmann, T; Müller, M: ROLE OF TUMOR SUPPRESSORS P53 AND P73 IN THE CELLULAR DEFENCE AGAINST HEPATITIS C VIRUS
P4_47
Scheurich, C; Tóth, I; Matzat, V; Kummer, S; Polywka, S; Meyer, T; Eiermann, T; Lohse, AW; Hartjen, P; van Lunzen, J; Schulze zur Wiesch, J: Fine Characterization and Determination of Cross-Reactivity of HCV-specific CD4+ T Cell Epitopes
P4_48
Schildberg, F; Höchst, B; Wojtalla, A; Siegmund, SV; Endl, E; Diehl, L; Abdullah, Z; Kurts, C; Knolle, PA: Hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism
P4_49
Schölzel, K; Schildberg, F; Knolle, PA; Stabenow, D: MHC class I transfer from stellate cells to LSEC allows for sinusoidal immunsurveillance
P4_50
Schuchmann, M; Kittner, JM; Schlaak, JF; Klaas, D; Eisenbach, C; Berg, T; Trautwein, C; Günther, R; Zeuzem, S; Goesseringer, R; Ehrlich, A; Neumann, K; Wachtlin, D; Boecher, WO; Galle, PR: All-trans retinoic acid co-administered with pegylated interferon and ribavirin does not influence viral kinetics in hepatitis C infected patients with previous non-response: Results of the ATRACTION study
P4_51
Sebode, M; Wiegard, C; Lohse, AW; Schramm, C; Weiler-Normann, C; Herkel, J: IFN-gamma und IL–17 Produktion durch SepSecS-reaktive T Zellen aus Patienten mit Autoimmuner Hepatitis
P4_52
Sibbing, B; Boesecke, C; Kokordelis, P; Baumgarten, A; Ingiliz, P; Mauss, S; Krämer, B; Eisenhardt, M; Glässner, A; Naumann, U; Söhne, J; Sauerbruch, T; Rockstroh, J; Spengler, U; Nattermann, J: Der CYP27B1–1260 Promoter Polymorphismus rs120877012 ist bei HCV/HIV koinfizierten Patienten signifikant mit einem Ansprechen auf die Therapie der Hepatitis C Erkrankung (SVR) assoziiert
P4_53
Skibbe, K; Giugliano, S; Scherbaum, N; Timm, J: The proapoptotic protein Bim is not differentially regulated in CD8+ T cells from resolved or chronic HCV infection
P4_54
Stiefel, J; Churin, Y; Roderfeld, M; Kopsch, K; Glebe, D; Roeb, E: Knochenmarktransplantation in HBV-transgenen Mäusen aggraviert die hepatische Fibrose
P4_55
Suneetha, PV; Pischke, S; Schlaphoff, V; Grabowski, J; Fytili, P; Gronert, A; Bremer, B; Markova, A; Jaroszewicz, J; Bara, CL; Manns, MP; Cornberg, M; Wedemeyer, H: HEV-specific T-cell responses are associated with control of HEV infection
P4_56
Tóth, I; Le, AQ; Hartjen, P; Thomssen, A; Beisel, C; Scheurich, C; Matzat, V; Kummer, S; Polywka, S; Frenzel, C; Lohse, AW; Lüth, S; van Lunzen, J; Schulze zur Wiesch, J: Downregulation of CD73 surface expression in regulatory as well as effector T cells in chronic HCV infection
P4_57
van Bömmel, F; Bartens, A; Mysickova, A; Brodzinski, A; Fülöp, B; Hofmann, J; Krüger, D; Berg, T; Edelmann, A: HBV messenger RNA (mRNA) is a strong predictive marker for HBeAg and HBsAg loss during antiviral treatment with nucleoside/nucleotide analogues (NUCs) in patients with chronic hepatitis B virus (HBV) infection
P4_58
van Heeswijk, R; Boogaerts, G; De Paepe, E; Vangeneugden, T; De Backer, K: Bioavailability of the HCV NS3/4A Protease Inhibitor Telaprevir–Effect of Different Types of Food
P4_59
van Heeswijk, R: Bioavailability of the HCV NS3/4A Protease Inhibitor Telaprevir – Effect of Different Types of Food
P4_60
Volz, T; Lütgehetmann, M; Allweiss, L; Lohse, AW; Petersen, J; Dandri, M: PRETREATMENT OF HUMANIZED uPA/SCID MICE WITH INTERFERON ALPHA STRONGLY INHIBITS THE ESTABLISHMENT OF HBV INFECTION
P4_61
Von Hahn, T; Schiene-Fischer, C; Steinmann, E; Strassburg, CP; Wedemeyer, H; Sarrazin, C; Müller, T; Berg, T; Manns, MP; Pietschmann, T; Ciesek, S: Variants in the human PPIA gene render host cells refractory to hepatitis C virus infection by destabilization of the essential host factor cyclophilin A
P4_62
Wegscheid, C; Panzer, U; Tiegs, G; Erhardt, A: Partial loss of immunological tolerance in CCR5-deficient mice in the murine model of concanavalin A-induced liver injury
P4_63
Wenzel, JJ; Faber, M; Huber, B; Stark, K; Jilg, W: Phylogenetic Characterization of HEV Isolates Derived from Acute Hepatitis E Cases in Germany 2010/2011
P4_64
Wiegand, S; Jaroszewicz, J; Zacher, B; Wursthorn, K; Deterding, K; Manns, MP; Wedemeyer, H; Cornberg, M: Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance
P4_65
Witthöft, T; Buggisch, P; Hüppe, D; Heyne, R; John, C; Möller, B; Moog, G; Schober, A; Schiffelholz, W; Baumgarten, A; Teuber, G; Lutz, T; Stoehr, A; Alshuth, U; Mauss, S: The Role of Weight Loss (WL) as On-Tretament Predictive Factor for SVR in the Treatment of Chronic Hepatitis C (CHC) Patients with Peginterferon alfa–2A (PEG) and Ribavirin (RBV)
P4_66
Wüstenberg, A; Keller, AD; Lehmann, E; Sirma, H; Bartenschlager, R; Lohmann, V; Loscher, C; Dandri, M; Tiegs, G; Sass, G: Induction of heme oxygenase 1 by HMG-CoA-Reductase inhibitors interferes with HCV replication
P4_67
Ziegler, S; Bröring, R; Gerken, G; Schlaak, JF; Timm, J: Presence of primary human hepatocytes inhibits expansion of virus-specific CD8+ T cells in vitro